NCT00136604 - Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m | Biotech Hunter

Enrollment

617

Participants

Timeline

Start Date

January 22, 2006

Primary Completion Date

April 23, 2006

Study Completion Date

April 23, 2006

Conditions

Whole Cell PertussisHaemophilus Influenzae Type bHepatitis BDiphtheriaTetanusDiphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Interventions

BIOLOGICAL

Tritanrix-HepB/Hib-MenAC

Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

BIOLOGICAL

Mencevax ACWY

GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine

BIOLOGICAL

Tritanrix-HepB/Hiberix

Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

BIOLOGICAL

Meningitec

Wyeth's MenC CRM197 conjugated vaccine, Meningitec

Trial Locations (3)

10400

GSK Investigational Site, Bangkok

40002

GSK Investigational Site, Khon Kaen

90110

GSK Investigational Site, Songkhla